Shar Pei Fever and Amyloidosis

Colleague,

Your presumptive diagnosis of Familial Shar Pei Fever (FSF) with secondary renal amyloidosis is very likely correct given the classic signalment, clinical signs, and significant proteinuria. This is a challenging condition, and your early identification of the renal component is key. Here is the management protocol I would initiate.

1. Prophylactic Anti-inflammatory Therapy:
The primary goal is to decrease the frequency and severity of the inflammatory episodes to reduce the rate of amyloid deposition.
* Colchicine: This is the mainstay of therapy. The standard dose is 0.025-0.03 mg/kg PO once daily for life. It is crucial to communicate to the owner that this is a prophylactic medication, not a treatment for acute febrile episodes. The most common side effect is dose-dependent GI upset (diarrhea, vomiting). If this occurs, we can try dose reduction or a brief drug holiday before re-initiating.

2. Management of Protein-Losing Nephropathy (PLN):
With a UPC of 3.2, this patient is in IRIS Stage 1 CKD but is substaged as proteinuric (P) and likely hypertensive (H, needs confirmation). We need to manage the PLN aggressively.
* ACE Inhibitor: Start benazepril (0.5 mg/kg PO q24h) or enalapril to target efferent arteriolar vasodilation and reduce glomerular pressure, thereby lowering proteinuria.
* Dietary Management: Transition to a prescription renal diet. These are protein- and phosphorus-restricted and supplemented with omega-3 fatty acids, which can have anti-inflammatory effects at the glomerular level.
* Thromboprophylaxis: Patients with PLN are hypercoagulable due to urinary loss of antithrombin III. I would strongly recommend starting clopidogrel at 2 mg/kg PO q24h to mitigate the risk of thromboembolic events.
* Blood Pressure Control: Systemic hypertension is a common and damaging sequela. If systolic blood pressure is consistently >160 mmHg, amlodipine (starting at 0.1-0.2 mg/kg PO q24h) should be added.

3. Monitoring Protocol:
* Baseline: Full CBC, chemistry panel, and urinalysis.
* 2-Week Recheck: After starting the ACE inhibitor and/or amlodipine, recheck creatinine, electrolytes, and blood pressure to ensure no acute kidney injury or significant hypotension has occurred.
* Long-term: Recheck chemistry, UPC, and blood pressure every 3-4 months initially. If the patient is stable (stable creatinine, >50% reduction in UPC), this interval can be extended to every 6 months.

Prognosis:
The prognosis is guarded. Once significant proteinuria develops, the renal amyloid deposition is advanced. Our goal is to slow progression, not reverse the existing damage. Some Shar Peis can be managed for several years with this protocol, but progression to end-stage renal failure is unfortunately common. The response of the UPC to therapy is a key prognostic indicator.

This is a comprehensive plan based on a highly probable diagnosis.
Confidence Level: High

Regards,
Dr. Elena Vasquez, DVM, DACVIM (SAIM)

This is a classic presentation, and your suspicion is high on my list as well. Managing the pharmacology here is critical to slowing the progression of the amyloidosis.

Colchicine Dosing & Mechanism
The primary goal of colchicine is prophylactic — to prevent the inflammatory cascades that lead to amyloid deposition. It will not treat an active fever spike.

* Dose: The standard evidence-based dose is 0.025-0.03 mg/kg PO once daily for life. Some clinicians divide this into a q12h schedule to mitigate GI upset, which is the most common dose-limiting side effect. I recommend starting at the lower end of the range (0.025 mg/kg q24h) with food and titrating up only if needed and tolerated.
* Mechanism: Colchicine inhibits microtubule polymerization, which in turn impairs neutrophil chemotaxis and degranulation. This blunts the acute inflammatory response characteristic of FSF episodes and reduces the production of serum amyloid A (SAA), the precursor protein to the amyloid fibrils that are destroying this dog's kidneys.

Pharmacologic Monitoring & Critical Considerations

Drug Interactions: Colchicine is a substrate for both Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Concurrent administration of potent inhibitors like ketoconazole, itraconazole, cyclosporine, or clarithromycin can dramatically increase colchicine levels and risk of toxicity (myelosuppression, severe GI signs). A thorough drug history is essential before starting.

Managing Febrile Episodes: This is the most critical point from a pharmacology standpoint. DO NOT use NSAIDs for the fever spikes. With a UPC of 3.2, this dog has significant glomerular disease and cannot tolerate the renal perfusion changes and potential nephrotoxic insult from NSAID therapy. This is a common and potentially catastrophic error in managing these cases. For fever management, focus on supportive care (cooling, hydration). If antipyretics are deemed essential, acetaminophen (10-15 mg/kg PO q12h, max 48h) is a much safer alternative in a dog with renal but not hepatic compromise.

Renal Function: While colchicine itself is not directly nephrotoxic, its clearance may be reduced in severe renal or hepatic failure. Given the existing proteinuria, you'll be monitoring renal values closely anyway as part of the disease management. If you see a significant decline in GFR (e.g., progression to IRIS Stage 3/4), a dose reduction of colchicine should be considered.

I'll defer to Dr. Vasquez for the specifics on monitoring the UPC and staging the amyloidosis, as well as the overall long-term prognosis. My role is to ensure the therapeutic plan doesn't inadvertently accelerate the renal decline. The immediate priority is initiating colchicine and educating the owner on the absolute contraindication for NSAIDs.